1-Piperazinyl compounds

Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. This includes bone and joint infections, intra-abdominal infections, certain types of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others. For some infections it is used in addition to other antibiotics. It can be taken by mouth, as eye drops, as ear drops, or intravenously.

Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.

Amoxapine, sold under the brand name Asendin among others, is a tricyclic antidepressant (TCA). It is the N-demethylated metabolite of loxapine. Amoxapine first received marketing approval in the United States in 1980, approximately 10 to 20 years after most of the other TCAs were introduced in the United States.

Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.

Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug used in the treatment of angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart. Developed and first marketed by Laboratoires Servier (France), it is described as the first cytoprotective anti-ischemic agent. Trimetazidine is an antianginal metabolic drug of the fatty acid oxidation inhibitor class; it shifts cardiac energy metabolism from fatty acid utilization toward glucose oxidation, thereby improving the efficiency of energy production in ischemic conditions.

chemical compound

Benzylpiperazine (BZP), also known as 1-benzylpiperazine, is a substance often used as a recreational drug and is known to have euphoriant and stimulant properties. Several studies conducted between 2000 and 2011 found that the effects of BZP are similar to amphetamine, although BZP's dosage is roughly 10 times higher by weight.

Enoxacin is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Insomnia is a common adverse effect. It is no longer available in the United States.

Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals.

Aminoethylpiperazine (AEP) is a derivative of piperazine. This ethyleneamine contains three nitrogen atoms; one primary, one secondary and one tertiary. It is a corrosive organic liquid and can cause second or third degree burns. Aminoethylpiperazine can also cause pulmonary edema as a result of inhalation. It is REACH and TSCA registered.

3-Trifluoromethylphenylpiperazine (TFMPP) is a recreational drug of the phenylpiperazine chemical class and is a substituted piperazine. Usually in combination with benzylpiperazine (BZP) and other analogues, it is sold as an alternative to the illicit drug MDMA ("Ecstasy").

Diphenylmethylpiperazine, also known as benzhydrylpiperazine, is a chemical compound and a piperazine derivative. It consists of a piperazine ring substituted with a benzhydryl (diphenylmethyl) group attached to one of the nitrogen atoms.

1-Cyclohexylpiperazine is a derivative of piperazine, and a precursor for PB-28.

Sarafloxacin (INN) is a quinolone antibiotic drug, which was removed from clinical use by its manufacturer Abbott Laboratories from April 30, 2001.

Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT3 receptor. It is a potent antiemetic and was in clinical trials for the treatment of nausea associated with cancer chemotherapy.

1-(2-Pyridinyl)piperazine is a chemical compound and piperazine derivative. Some derivatives of this substance are known to act as potent and selective α2-adrenergic receptor antagonists, such as 1-(3-fluoro-2-pyridinyl)piperazine.

SB-357134 is a drug which is used in scientific research. It acts as a potent, selective and orally active 5-HT6 receptor antagonist. SB-357134 and other 5-HT6 antagonists show nootropic effects in animal studies, and have been proposed as potential novel treatments for cognitive disorders such as schizophrenia and Alzheimer's disease.

Eltoprazine (; developmental code name DU-28,853) is a non-selective serotonin receptor modulator of the phenylpiperazine family which was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, drug-induced dyskinesia, and psychotic disorders but was never marketed. It has been described as a "serenic" or antiaggressive agent. The drug is taken orally.

Batoprazine is a drug of the phenylpiperazine class which has been described as a serenic or antiaggressive agent. It acts as a 5-HT1A and 5-HT1B receptor agonist. It is closely related to eltoprazine, fluprazine, and naphthylpiperazine, of which possess similar actions and effects.

SRT-1720 is an experimental drug that was studied by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. The compound has been studied in animals, but safety and efficacy in humans have not been established.

7-Hydroxyamoxapine is an active metabolite of the antidepressant drug amoxapine (Asendin). It contributes to amoxapine's pharmacology. It is a dopamine receptor antagonist and contributes to amoxapine's antipsychotic properties.

SB-399885 is a drug which is used in scientific research. It acts as a potent, selective and orally active 5-HT6 receptor antagonist, with a Ki of 9.0nM. SB-399885 and other 5-HT6 antagonists show nootropic effects in animal studies, as well as antidepressant and anxiolytic effects which are comparable to and synergistic with drugs such as imipramine and diazepam, and have been proposed as potential novel treatments for cognitive disorders such as schizophrenia and Alzheimer's disease.

'''N-Methylpiperazine''' is a heterocyclic organic compound.

1-(2-Diphenyl)piperazine, also known as RA-7, is a drug that acts as a potent and selective antagonist at the 5HT serotonin receptor. It was discovered as an active metabolite of the synthetic 5-HT agonists LP-12 and LP-211 and unexpectedly turned out to be a potent antagonist with selectivity approaching that of the parent molecules, despite its much simpler structure.

4-Bromo-2,5-dimethoxy-1-benzylpiperazine (2C-B-BZP) is a psychoactive drug and research chemical of the piperazine chemical class which has been sold as a "designer drug". It produces stimulant effects similar to those of benzylpiperazine (BZP).

MDBZP, also known as 1-(3,4-methylenedioxybenzyl)piperazine or as piperonylpiperazine, is a chemical compound of the benzylpiperazine family related to benzylpiperazine (BZP). MDBZP has been sold as a designer drug and has even been found as an ingredient in street Ecstasy pills.

Pitrazepin is a competitive GABAA and glycine receptor antagonist. It has been used to study insect and snail nervous systems in scientific research.

CP-809101 is a drug which acts as a potent and highly selective serotonin 5-HT2C receptor full agonist. It had promising results in animal models of obesity and psychosis, but associated with genotoxicity which means that future use will be restricted to scientific research applications only.

SB-271046 is a drug which is used in scientific research. It was one of the first selective 5-HT6 receptor antagonists to be discovered, and was found through high-throughput screening of the SmithKline Beecham Compound Bank using cloned 5-HT6 receptors as a target, with an initial lead compound being developed into SB-271046 through a structure-activity relationship (SAR) study. SB-271046 was found to be potent and selective in vitro and had good oral bioavailability in vivo, but had poor penetration across the blood–brain barrier, so further SAR work was then conducted, which led to improved